Orchestra BioMed Holdings Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Orchestra BioMed Holdings stock has a consensus rating of "Strong Buy" and an average price target of $12.17. The average 1-year stock price forecast is 208.10% higher than the current stock price, while the lowest is $9.00 (+127.85%) and the highest is $20 (+406.33%).

Price Target: $12.17 (+208.10%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$9.00	$12.17	$10	$20
Change	+127.85%	+208.10%	+153.16%	+406.33%

Analyst Ratings

The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Mar '26	Apr '26	May '26
Strong Buy	4	5	5	5	5	5
Buy	2	2	2	2	2	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	8	8	8	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anderson Schock B. Riley Securities	B. Riley Securities	Buy Reiterates $12 → $10	Buy	Reiterates	$12 → $10	+153.16%	May 19, 2026
Yi Chen H.C. Wainwright	H.C. Wainwright	Buy Reiterates $10	Buy	Reiterates	$10	+153.16%	May 14, 2026
Matthew O'Brien Piper Sandler	Piper Sandler	Buy Maintains $9	Buy	Maintains	$9	+127.85%	May 13, 2026
Matt Miksic Barclays	Barclays	Buy Reiterates $12 → $13	Buy	Reiterates	$12 → $13	+229.11%	May 13, 2026
Josh Jennings TD Cowen	TD Cowen	Buy Reiterates $15	Buy	Reiterates	$15	+279.75%	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

476.33K

from 33.48M

-98.58%

from 33.48M

Revenue Next Year

661.14K

from 476.33K

38.80%

from 476.33K

EPS This Year

-1.47

from -1.11

EPS Next Year

-1.46

from -1.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-782.00K	3.53M	2.76M	2.64M	33.48M	476.33K
Revenue Growth	-	-	-21.88%	-4.42%	1,169.22%	-98.58%
Gross Profit	-981.00K	3.32M	2.57M	2.43M	33.29M	332.00K
Gross Margin	125.45%	94.03%	93.26%	92.27%	99.43%	69.70%
Operating Income	-21.80M	-32.66M	-51.51M	-64.30M	-51.81M	-96.08M
Net Income	-23.01M	-33.61M	-49.12M	-61.02M	-52.70M	-94.78M
EPS	-	-	-	-	-1.11	-1.47
Free Cash Flow	-13.86M	-10.06M	-33.04M	-25.45M	-20.25M	-77.80M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	575,000
Avg	476,330
Low	400,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	-98.3%
Avg	-98.6%
Low	-98.8%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.47
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-